ArticleOncotarget2017
Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- 8 specific Chinese herbal injections combined with chemotherapy for breast cancer: a systematic review and network meta-analysis of comparative safety and efficacy.Frontiers in pharmacology · 2025Pooled it
- Utility of CA-125 for diagnosis and prognosis of breast cancer: a systematic review.Exploration of targeted anti-tumor therapy · 2025Pooled it
- The association between endometriosis and risk of endometrial cancer and breast cancer: a meta-analysis.BMC women's health · 2022Pooled it
- Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Pooled it
- Development and validation of a model and nomogram for breast cancer diagnosis based on quantitative analysis of serum disease-specific haptoglobin N-glycosylation.Journal of translational medicine · 2024Trial
- NAV-005, a high-affinity MUC16/CA125 antagonist for the treatment of humoral immunosuppressed cancers.BMC cancer · 2026Article
- Application of Shear Wave Elastography Combined with Tumor Markers in the Differential Diagnosis of Benign and Malignant Breast Masses.Breast cancer (Dove Medical Press) · 2026Article
- Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer.Frontiers in oncology · 2026Article
- A2M-AS1, DBH-AS1, and NCBP2-AS2 in breast cancer: expression patterns, CA125-3 association, and a DBH-AS1-NCBP2-AS2 axis.Molecular biology reports · 2025Article
- The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis.Journal of cancer research and clinical oncology · 2025Review
- The kinetics of CA125 levels as a prognostic marker for in-hospital mortality in patients with acute heart failure: a pilot study.Frontiers in cardiovascular medicine · 2025Article
- The Effects of Preoperative Serum Carcinoembryonic Antigen, Cancer Antigen 15-3 and Cancer Antigen 125 on the Prognosis of Breast Cancer Patients With Different Molecular Subtypes.Journal of clinical medicine research · 2024Article
- Screen-Printed Electrodes as Low-Cost Sensors for Breast Cancer Biomarker Detection.Sensors (Basel, Switzerland) · 2024Review
- Anti-tumoral Immunity and Chemo-preventive Effectiveness of Herbal Extracts of Curcumin, Ginger, Clove and Amygdaline in Ehrlich Ascites Carcinoma-Challenging Mice.Anti-cancer agents in medicinal chemistry · 2024Article
- Bio-Guided Assay ofMolecules (Basel, Switzerland) · 2023Article
- Structure-Based Multi-Targeted Molecular Docking and Dynamic Simulation of Soybean-Derived Isoflavone Genistin as a Potential Breast Cancer Signaling Proteins Inhibitor.Life (Basel, Switzerland) · 2023Article
- A review of prognostic and predictive biomarkers in breast cancer.Clinical and experimental medicine · 2023Review
- Quantitative analysis of serum cell-free DNA as a predictive and prognostic marker in breast cancer patients.Frontiers in oncology · 2023Article
- Rational Approach to Finding Genes Encoding Molecular Biomarkers: Focus on Breast Cancer.Genes · 2022Article
- Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study.BMC cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detection of serum tumor markers has been developed as a non-invasive tool to assess treatment efficiency in different types of cancer. This study aims to investigate the role of preoperative serum tumor markers (CEA, CA125 and CA15-3) in the management of breast cancer, and their relationships with patients' clinicopathological parameters as well as different molecular subtypes. Altogether, 151 patients with invasive breast cancer and 180 control subjects with benign breast diseases were enrolled in this study. In the present study, preoperative serum levels of CEA, CA125 and CA15-3 were significantly higher in patients with breast cancer than controls subjects. Moreover, late-stage cancer patients exhibited significantly higher levels of CEA, CA125 and CA15-3 compared with early-stage ones. Statistical analysis indicated that elevated CA125 and CA15-3 levels were obviously related to patients with larger tumor diameter (>5cm) and lymph node metastasis. Furthermore, our results showed that the preoperative serum levels of CA125 exhibited statistical differences among various molecular subtypes, with the most frequent elevations occurring in the triple-negative tumors. In summary, our study indicated that the preoperative serum levels of CEA, CA125 and CA15-3 might be more efficient for monitoring advanced tumors than early diagnosis. High preoperative CA125 levels may reflect tumor burden and are associated with aggressive molecular subtype, suggesting that it can be used to predict poor outcome and prognosis of breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.